Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F C Moazedi-Fuerst

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical and Experimental Dermatology|September 25, 2014
Dosage of rituximab in systemic sclerosis: 2-year results of five casesF C Moazedi-Fuerst, S M Kielhauser, K Bodo, et al.
Scandinavian Journal of Rheumatology|September 18, 2015
Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: a promising surveillance marker of therapy?F C Moazedi-Fuerst, S M Kielhauser, J Hermann, et al.
Scandinavian Journal of Rheumatology|March 12, 2014
Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimenF C Moazedi-Fuerst, S M Kielhauser, K Brickmann, et al.
Clinical and Experimental Rheumatology|March 20, 2014
Ultrasound screening for interstitial lung disease in rheumatoid arthritisF C Moazedi-Fuerst, S M Kielhauser, S Scheidl, et al.
Clinical Rheumatology|August 21, 2012
Pulmonary echography in systemic sclerosisF C Moazedi-Fuerst, P M Zechner, N J Tripolt, et al.
Zeitschrift Fur Rheumatologie|May 5, 2022
[Value of CT and transthoracic lung ultrasound in patients with systemic sclerosis : Joint statement of the ÖRG/ÖGP/ÖGR/ÖGUM]M Grohs, F C Moazedi-Fuerst, H Flick, et al.
Journal of Autoimmunity|May 24, 2024
Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapyF C Moazedi-Fuerst, A Lackner, S M Kreuzer, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical and Experimental Dermatology|September 25, 2014
Dosage of rituximab in systemic sclerosis: 2-year results of five casesF C Moazedi-Fuerst, S M Kielhauser, K Bodo, et al.
Scandinavian Journal of Rheumatology|September 18, 2015
Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: a promising surveillance marker of therapy?F C Moazedi-Fuerst, S M Kielhauser, J Hermann, et al.
Scandinavian Journal of Rheumatology|March 12, 2014
Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimenF C Moazedi-Fuerst, S M Kielhauser, K Brickmann, et al.
Clinical and Experimental Rheumatology|March 20, 2014
Ultrasound screening for interstitial lung disease in rheumatoid arthritisF C Moazedi-Fuerst, S M Kielhauser, S Scheidl, et al.
Clinical Rheumatology|August 21, 2012
Pulmonary echography in systemic sclerosisF C Moazedi-Fuerst, P M Zechner, N J Tripolt, et al.
Zeitschrift Fur Rheumatologie|May 5, 2022
[Value of CT and transthoracic lung ultrasound in patients with systemic sclerosis : Joint statement of the ÖRG/ÖGP/ÖGR/ÖGUM]M Grohs, F C Moazedi-Fuerst, H Flick, et al.
Journal of Autoimmunity|May 24, 2024
Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapyF C Moazedi-Fuerst, A Lackner, S M Kreuzer, et al.
Pageof 1